Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 17/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL463006 | 1.00 | DGAT1 (0.49) | DGAT1ALDH1A1KDM5BPOLBCASP3 | |
| SCHEMBL439167 | 0.90 | DGAT1 (0.51) | DGAT1ALDH1A1 | |
| SCHEMBL439166 | 0.90 | DGAT1 (0.51) | DGAT1ALDH1A1 | |
| SCHEMBL442372 | 0.88 | DGAT1 (0.49) | DGAT1ALDH1A1KDM5BPOLB | |
| SCHEMBL440436 | 0.88 | DGAT1 (0.49) | DGAT1KDM5B | |
| SCHEMBL440437 | 0.88 | DGAT1 (0.49) | DGAT1KDM5B | |
| SCHEMBL441745 | 0.86 | DGAT1 (0.51) | DGAT1 | |
| SCHEMBL441744 | 0.86 | DGAT1 (0.51) | DGAT1 | |
| SCHEMBL442873 | 0.85 | DGAT1 (0.54) | DGAT1ALDH1A1KDM5B | |
| SCHEMBL463142 | 0.85 | DGAT1 (0.50) | DGAT1ALDH1A1KDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | DGAT1 2/4885ALDH1A1 272/4885KDM5B 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.